Finance

Lists
Why is 51S up 9,09%?
Dive Deeper
51S:FRA
Cynata Therapeutics Ltd
€0,0060
+9,09%
(+0,00050) 1D
8 Okt., 08:02:37 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 51S...
Open
€0,01
High
€0,01
Low
€0,01
Mkt. cap
3,21 m
Avg. vol.
0,00
Volume
0,00
52-wk high
€0,24
52-wk low
€0,00
No. of employees
0
Open
€0,01
High
€0,01
Low
€0,01
Mkt. cap
3,21 m
Avg. vol.
0,00
Volume
0,00
52-wk high
€0,24
52-wk low
€0,00
No. of employees
0
News stories
From web sources and news partners
About Cynata Therapeutics Ltd
CEORoss Alexander Macdonald
Employees0
Founded2003
Headquarters-
Sector-
Websitecynata.com
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
855,81 k
855,81 k
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
2,77 m
2,77 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,69 m
1,69 m
-763,69 k
-763,69 k
Operating expense
2,22 m
2,22 m
2,63 m
2,63 m
Total operating expenses
2,22 m
2,22 m
2,63 m
2,63 m
Operating income
-1,36 m
-1,36 m
-2,63 m
-2,63 m
Other non operating income
-
-
-
-
EBT including unusual items
-1,33 m
-1,33 m
-3,29 m
-3,29 m
EBT excluding unusual items
-1,33 m
-1,33 m
-2,62 m
-2,62 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
425,31 k
425,31 k
527,43 k
527,43 k
Net income
-1,33 m
-1,33 m
-3,29 m
-3,29 m
Net profit margin
-155,55%
-155,55%
-
-
Earnings per share
-
-
-
-
Interest and investment income
30,33 k
30,33 k
9,42 k
9,42 k
Interest expense
-
-
-
-
Net interest expenses
30,33 k
30,33 k
9,42 k
9,42 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,30 m
-1,30 m
-2,56 m
-2,56 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme